Status:
COMPLETED
Prospective Trial for Examining Hematuria Using Computed Tomography
Lead Sponsor:
Oslo University Hospital
Conditions:
Urothelial Carcinoma
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary objective is to evaluate whether one-phase nephrographic CT (experimental) is sufficient to detect urothelial cell carcinoma in patients with hematuria compared to the traditional four-pha...
Detailed Description
Responsible centers Oslo University Hospital, Aker. Division of Radiology and Nuclear medicine. Study type: Prospective clinical trial Study design: One sample paired proportion, non-inferiority stu...
Eligibility Criteria
Inclusion
- Asymptomatic macroscopic hematuria referred to CTU before cystoscopy
- \>18 years old
Exclusion
- Symptomatic urinary tract infection relieved by antibiotics
- Patients referred to CTU after cystoscopy
- Cystoscopy within the last 6 months
- Symptomatic stone disease
- Macroscopic hematuria after recent catherization or instrumentation
- Microscopic hematuria
- Previous history of Urothelial cell carcinoma
- Known staghorn calculi
- Allergy to iodine contrast media
- Impaired renal function (eGFR \< 30m/min/1.73m2)
- Unable to provide consent for any reason
- For any reason, do not wish to participate in the study
Key Trial Info
Start Date :
September 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04077359
Start Date
September 15 2019
End Date
July 1 2021
Last Update
September 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway, 0524